Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.40 |
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29459925 | 1.00 | RIPK1 (0.47) | RIPK1CES2CES1TSHRCXCL8 | |
| SCHEMBL6858266 | 0.85 | RIPK1 (0.49) | RIPK1CES2CES1 | |
| SCHEMBL12984533 | 0.82 | RIPK1 (0.46) | RIPK1CES2CES1 | |
| SCHEMBL15271780 | 0.82 | RIPK1 (0.50) | RIPK1CES2CES1 | |
| SCHEMBL29517836 | 0.82 | RIPK1 (0.50) | RIPK1CES2CES1 | |
| SCHEMBL29017067 | 0.82 | RIPK1 (0.46) | RIPK1CES2CES1 | |
| SCHEMBL30428405 | 0.81 | CXCL8 (0.41) | CES2CES1TSHRCXCL8AKR1B1 | |
| SCHEMBL7249684 | 0.81 | CXCL8 (0.41) | CES2CES1TSHRCXCL8AKR1B1 | |
| SCHEMBL584220 | 0.80 | FFAR1 (0.47) | RIPK1CES2CES1 | |
| SCHEMBL20440116 | 0.80 | AGBL2 (0.39) | RIPK1CES2CES1TSHRCXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114715-B1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | SIEMENS AG (DE) | 2019-10-30 | — | — | EP | claimed |
| EP-4737458-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250185502-A1 | ORGANIC OPTOELECTRONIC COMPONENT, ORGANIC FUNCTIONAL LAYER, AND METHOD FOR PRODUCING AN OPTOELECTRONIC COMPONENT | OSRAM OLED GMBH (DE) | 2025-06-05 | — | — | US | disclosed |
| US-12302747-B2 | Optoelectronic component, organic functional layer, and method for producing an optoelectronic component | OSRAM OLED GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| EP-4193399-B1 | ELECTRONIC DEVICE | MERCK PATENT GMBH (DE) | 2025-01-29 | — | — | EP | disclosed |
| EP-3210248-B2 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2024-04-10 | — | — | EP | disclosed |
| EP-4193399-A2 | ELECTRONIC DEVICE | Merck Patent GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| CN-116194434-A | Electronic device | 默克专利有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116102556-A | Preparation method of sitagliptin intermediate | 重庆普佑生物医药有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-111187154-B | Synthetic method of sitagliptin intermediate 2,4, 5-trifluoro phenylacetic acid | 浙江九洲药业股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| WO-2013169348-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013138418-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138418-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | WO | disclosed |
| CN-102917588-A | Chemical compounds | GLAXOSMITHKLINE LLC | 2013-02-06 | — | — | CN | disclosed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| EP-0394644-A2 | Halobenzene derivatives | BAYER AG (DE) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | RIPK1 218/4885CES2 2996/4885CES1 738/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | RIPK1 218/4885CES2 2996/4885CES1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.